 The initial proposed dose level in our study will be 3.2mgkg of body weight over 6 hours for 3 days. The next levels will be 3.2mgkg of body weight over 6 hours for 4 days, 4.3 mgkg of body weight over 6 hours for 3 days, 5.6 mgkg of body weight over 6 hours for 2 days, and 6.4 mgkg of body weight over 6 hours for 2 days. Three patients per group will be entered at the first level. Further enrollment will be dependent upon toxicities observed. All dose escalations will be initiated after the PI has reviewed the toxicity data available on the prior dose levels and confirms that it is safe to proceed to subsequent dose levels. Maximum tolerated dose will defined as the dose level immediately below the dose level at which 2 of 6 patients experiences a grade 4 non-hematological toxicity that is unexpected, related, and serious, and it will be evaluated separately for patients 65 years of age or in patients with renal insufficiency. 